Search Results - "Koolen, S."

Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study by Groenland, S.L., van Eerden, R.A.G., Westerdijk, K., Meertens, M., Koolen, S.L.W., Moes, D.J.A.R., de Vries, N., Rosing, H., Otten, H., Vulink, A.J.E., Desar, I.M.E., Imholz, A.L.T., Gelderblom, H., van Erp, N.P., Beijnen, J.H., Mathijssen, R.H.J., Huitema, A.D.R., Steeghs, N.

“…Oral targeted therapies show a high pharmacokinetic (PK) interpatient variability. Even though exposure has been positively correlated with efficacy for many…”
Get full text

Pemetrexed exposure predicts toxicity in advanced non–small-cell lung cancer: A prospective cohort study by Visser, S., Koolen, S.L.W., de Bruijn, P., Belderbos, H.N.A., Cornelissen, R., Mathijssen, R.H.J., Stricker, B.H., Aerts, J.G.J.V.

“…We explored whether total exposure to pemetrexed predicts effectiveness and toxicity in advanced non–small-cell lung cancer (NSCLC). Furthermore, we…”
Get full text

Towards a farmer-feasible soil health assessment that is globally applicable by Hughes, H.M., Koolen, S., Kuhnert, M., Baggs, E.M., Maund, S., Mullier, G.W., Hillier, J.

“…Globally, agriculture has had a significant and often detrimental impact on soil. The continued capacity of soil to function as a living ecosystem that…”
Get full text

A new method for the determination of total and released docetaxel from docetaxel-entrapped core-crosslinked polymeric micelles (CriPec®) by LC–MS/MS and its clinical application in plasma and tissues in patients with various tumours by Braal, C.L., de Bruijn, P., Atrafi, F., van Geijn, M., Rijcken, C.J.F., Mathijssen, R.H.J., Koolen, S.L.W.

“…•CriPec® docetaxel leads ideally via more selective tumour targeting to higher intratumoural drug concentrations.•This method was developed and validated for…”
Get full text

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001) by Moes, J.J., Koolen, S.L.W., Huitema, A.D.R., Schellens, J.H.M., Beijnen, J.H., Nuijen, B.

“…For use in chronic oral chemotherapeutic regimens, the potent anticancer drug docetaxel needs a solid oral dosage form. Because docetaxel has a very low…”
Get full text

Intravenous-to-Oral Switch in Anticancer Chemotherapy: A Focus on Docetaxel and Paclitaxel by Koolen, S L W, Beijnen, J H, Schellens, J H M

“…Oral administration of the taxanes docetaxel and paclitaxel is hampered by their affinity for drug transporters, especially ABCB1 (P‐glycoprotein, Pgp);…”
Get full text

Clinical implications of nintedanib pharmacokinetics in patients with pulmonary fibrosis by Agema, B.C., Berrich, M., Seuren, L., Sassen, S.D.T., Miedema, J.R., Koch, B.C.P., Wijsenbeek, M.S., Koolen, S.L.W., Mathijssen, R.H.J., Veerman, G.D.M.

“…Nintedanib is used to treat both idiopathic and progressive pulmonary fibrosis (IPF/PPF). Evidence of both an exposure-response relationship and an…”
Get full text

The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer by Buijs, S.M., Hoop, E. Oomen-de, Braal, C.L., van Rosmalen, M.M., Drooger, J.C., van Rossum-Schornagel, Q.C., Vastbinder, M.B., Koolen, S.L.W., Jager, A., Mathijssen, R.H.J.

“…Tamoxifen is important in the adjuvant treatment of hormone-sensitive breast cancer and substantially reduces recurrence; however, almost 50% of patients are…”
Get full text

Incidence of clinically significant toxicities in patients with high endoxifen concentrations by Groenland, S.L., Sanchez-Spitman, A.B., Moes, D.J.A.R., Koolen, S.L., Dezentjé, V.O., van Erp, N., Mathijssen, R.H.J., Guchelaar, H.-J., Huitema, A.D.R., Steeghs, N.

Get full text

Monitoring in language perception in high-functioning adults with autism spectrum disorder: Evidence from event-related potentials by Koolen, S, Vissers, C.Th.W.M, Egger, J.I.M, Verhoeven, L

“…Highlights • We studied language problems in autism spectrum disorder (ASD) in light of monitoring, an aspect of cognitive control, using event-related…”
Get full text

Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes by Giraud, E.L., Westerdijk, K., van der Kleij, M.B.A., Guchelaar, N.A.D., Meertens, M., Bleckman, R.F., Rieborn, A., Mohammadi, M., Roets, E., Mathijssen, R.H.J., Huitema, A.D.R., Koolen, S.L.W., Gelderblom, H., Moes, D.J.A.R., Reyners, A.K.L., Touw, D.J., Keizer-Heldens, P., Oosten, A.W., van der Graaf, W.T.A., Steeghs, N., van Erp, N.P., Desar, I.M.E.

“…Sunitinib is an oral anticancer drug approved for the treatment of among others gastrointestinal stromal tumor (GIST). Previous analyses demonstrated an…”
Get full text

From Mouse to Man: Predictions of Human Pharmacokinetics of Orally Administered Docetaxel From Preclinical Studies by Koolen, S. L. W., van Waterschoot, R. A. B., van Tellingen, O., Schinkel, A. H., Beijnen, J. H., Schellens, J. H. M., Huitema, A. D. R.

“…Intravenously administered docetaxel is approved for the treatment of various types of cancer. An oral regimen, in combination with ritonavir, is being…”
Get full text

The impact of therapeutic drug monitoring-based tamoxifen dose-reductions on endocrine side effects in patients with primary breast cancer by Buijs, S., Braal, L., Oomen-de Hoop, E., van Rosmalen, M., Drooger, J., van Rossum-Schornagel, Q., Vastbinder, M., Koolen, S., Jager, A., Mathijssen, R.

Get full text

769P Pharmacokinetic boosting of olaparib: An open-label, prospective, cross-over study by Overbeek, J., Guchelaar, N., Mohmaed Ali, M.I., Ottevanger, P.B., Bloemendal, H., Koolen, S., Mathijssen, R., Boere, I., Hamberg, P., Huitema, A., Sonke, G., Opdam, F., Ter Heine, R., Van Erp, N.

Get full text

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose by Westerdijk, Kim, Desar, Ingrid M.E., Steeghs, Neeltje, Graaf, Winette T.A., Erp, Nielka P.

“…Tyrosine kinase inhibitors (TKIs) are anti‐cancer drugs that target tyrosine kinases, enzymes that are involved in multiple cellular processes. Currently,…”
Get full text

P10.24.B SCREENING NON-ONCOLOGICAL DRUGS IN A PATIENT-DERIVED GLIOBLASTOMA MODEL IDENTIFIES PITAVASTATIN WITH POTENTIAL ANTITUMOR ACTIVITY by Zekanovic, S, Achaiber Sing, P, Basuki, A, Koolen, S L W, Ntafoulis, I, den Hollander, C W J, Chien, M P, Li, Y, Mustafa, D A M, Dirven, C M F, Leenstra, S, Lamfers, M L M

“…Abstract BACKGROUND Glioblastoma (GBM) is a malignancy which is in dire need of novel treatment options. Repurposing non-oncological drugs has become of great…”
Get full text

P10.23.A A PATIENT-DERIVED FUNCTIONAL GBM DRUG SCREEN OFFERS A TOOL TO PREDICT TMZ RESPONSE AND ASSESS SENSITIVITY TO CANDIDATE TREATMENTS ON A PER PATIENT BASIS by Ntafoulis, I, Kleijn, A, Posthoorn-Verheul, C, Koolen, S, Jimenez-Cowell, K, Kers, T, Klein, M, den Hollander, C, Ju, J, Li, Y, Stubbs, A, Dirven, C, Leenstra, S, Lamfers, M

“…Abstract BACKGROUND Major obstacles that have impeded the development of effective new therapies for GBM include inter- and intratumoral heterogeneity, the…”
Get full text

296PPatient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach by Mueller-Schoell, A, Klopp-Schulze, L, Huisinga, W, Joerger, M, Neven, P, Koolen, S L, Mathijssen, R H J, Schmidt, S, Kloft, C

“…Abstract Background About 20% of breast cancer (BC) patients do not attain tamoxifen’s (TAM) active metabolite endoxifen (ENDX) target concentrations when…”
Get full text

P10.28.B INTERMODEL VARIATION OF BBB PERMEABILITY AFFECTS CNS DRUG DELIVERY IN PDX MODELS OF GBM by Ntafoulis, I, Koolen, S L W, den Hollander, C W J, Goedknegt, E, Haeck, J, Kers, T V, Dijkhuizen, S, van Dis, V, van den Bosch, T P P, Gao, Z, Mezzanotte, L, van Tellingen, O, Dirven, C M F, Leenstra, S, Lamfers, M L M

“…Abstract BACKGROUND Little progress has been made in the development of effective new therapies for glioblastoma (GBM) the past decades. One of the major…”
Get full text

Prevention of VEGF inhibitor-induced toxicity by salt restriction: the SUN-SALT study by Van Doorn, L, Visser, W J, Van Dorst, D C H, Mirabito Colafella, K M M, Koolen, S L W, Van Egmond-De Mik, A M E, Oomen-De Hoop, E, Bins, S, Hoorn, E J, Danser, A H, Mathijssen, A H, Versmissen, J

“…Abstract Introduction Vascular endothelial growth factor (VEGF) inhibitors target the formation of new blood vessels required for growth and metastatic spread…”
Get full text